Supplementary Figure 12 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Multivariate Cox analysis of change in cancer mutation concentration (CMC) from baseline to cycle 3 of pembrolizumab. Covariates include cohort, PD-L1 expression, and tumor mutation burden